GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » Price-to-Owner-Earnings

INmune Bio (INmune Bio) Price-to-Owner-Earnings : (As of May. 31, 2024)


View and export this data going back to 2019. Start your Free Trial

What is INmune Bio Price-to-Owner-Earnings?

As of today (2024-05-31), INmune Bio's share price is $9.28. INmune Bio does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for INmune Bio's Price-to-Owner-Earnings or its related term are showing as below:


INMB's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.61
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-31), INmune Bio's share price is $9.28. INmune Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.92. Therefore, INmune Bio's PE Ratio for today is At Loss.

As of today (2024-05-31), INmune Bio's share price is $9.28. INmune Bio's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.92. Therefore, INmune Bio's PE Ratio without NRI for today is At Loss.


INmune Bio Price-to-Owner-Earnings Historical Data

The historical data trend for INmune Bio's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio Price-to-Owner-Earnings Chart

INmune Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

INmune Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of INmune Bio's Price-to-Owner-Earnings

For the Biotechnology subindustry, INmune Bio's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INmune Bio's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where INmune Bio's Price-to-Owner-Earnings falls into.



INmune Bio Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

INmune Bio's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=9.28/-1.89
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


INmune Bio  (NAS:INMB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


INmune Bio Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of INmune Bio's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


INmune Bio (INmune Bio) Business Description

Traded in Other Exchanges
N/A
Address
225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Executives
Scott Juda director 325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Timothy J Schroeder director 2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
David J Moss 10 percent owner, officer: CFO, Treasurer & Secretary C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi director, 10 percent owner, officer: President & CEO 476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Mark William Lowdell 10 percent owner, officer: Chief Scientific Officer THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Linda F Powers 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei director 10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen director P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini director C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc 10 percent owner 465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski director 241 WEST PALM AVENUE, MONROVIA CA 91016

INmune Bio (INmune Bio) Headlines

From GuruFocus

INmune Bio Inc (INMB) Reports Q3 2023 Financial Results

By GuruFocus Research 11-01-2023